Gene Expression Regulation in the Mouse Liver by Mechanistic Target Of Rapamycin Complexes I and II by Poluyanoff, Anthony
University of Massachusetts Amherst 
ScholarWorks@UMass Amherst 
Masters Theses Dissertations and Theses 
July 2020 
Gene Expression Regulation in the Mouse Liver by Mechanistic 
Target Of Rapamycin Complexes I and II 
Anthony Poluyanoff 
Follow this and additional works at: https://scholarworks.umass.edu/masters_theses_2 
 Part of the Molecular Biology Commons 
Recommended Citation 
Poluyanoff, Anthony, "Gene Expression Regulation in the Mouse Liver by Mechanistic Target Of 
Rapamycin Complexes I and II" (2020). Masters Theses. 900. 
https://scholarworks.umass.edu/masters_theses_2/900 
This Open Access Thesis is brought to you for free and open access by the Dissertations and Theses at 
ScholarWorks@UMass Amherst. It has been accepted for inclusion in Masters Theses by an authorized 
administrator of ScholarWorks@UMass Amherst. For more information, please contact 
scholarworks@library.umass.edu. 
 
 
 
 
 
 
 
 
 
Gene expression regulation in the mouse liver by mechanistic target of 
rapamycin complexes I and II 
 
 
 
 
 
 
 
 
A Thesis Presented 
 
 
by 
 
ANTHONY ALEXANDER POLUYANOFF 
 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate School of the 
University of Massachusetts Amherst in partial fulfillment 
of the requirements for the degree of 
 
Master of Science 
 
May 2020 
 
Molecular and Cellular Biology
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Copyright by Anthony Alexander Poluyanoff 2020 
 
All Rights Reserved 
 
 Gene expression regulation in the mouse liver by mechanistic target of 
rapamycin complexes I and II 
 
 
 
 
 
 
 
A Thesis Presented 
 
by 
 
ANTHONY ALEXANDER POLUYANOFF 
 
 
 
 
 
 
Approved as to style and content by: 
 
 ____________________________________________________ 
Alexander Suvorov, Chair 
 
 
 ____________________________________________________ 
J. Richard Pilsner, Member 
 
 
 ____________________________________________________ 
Laura N. Vandenberg, Member 
 
 
 ________________________________________________  
Scott C. Garman, Director, Molecular and Cellular 
Biology Program 
 iv 
 
ABSTRACT 
GENE EXPRESSION REGULATION IN THE MOUSE LIVER BY 
MECHANISTIC TARGET OF RAPAMYCIN COMPLEXES I AND II 
MAY 2020 
 
ANTHONY ALEXANDER POLUYANOFF, B.S., UNIVERSITY OF MASSACHUSETTS, AMHERST 
 
M.S., UNIVERSITY OF MASSACHUSETTS, AMHERST 
 
Directed by: Professor Alexander Suvorov 
 
     The mechanistic target of rapamycin (mTOR) is a key serine/threonine protein kinase 
that functions in complexes mTORC1 and mTORC2. mTORC1, originally discovered due 
to its sensitivity towards the mTOR inhibitor rapamycin, responds to extracellular growth 
factor signaling, WNT signaling, and nutrient abundance via glucose and amino acid-
triggered signaling. Downstream effectors of mTORC1 include autophagy, mitochondrial 
metabolic function, protein synthesis, and ribosome biogenesis. mTORC2, initially 
discovered as a rapamycin-insensitive complex of mTOR, responds to insulin, growth 
factor signaling, and inflammatory signaling such as tumor necrosis factor-alpha, with its 
downstream effectors being Akt, a key serine/threonine kinase that functions in cell 
division and is frequently dysregulated in many types of cancer, the NFkB pathway, and 
cytoskeletal reorganization and protein synthesis. Much research has been devoted to 
mTORC1 signaling, with mTORC2 receiving significantly less attention, despite both 
complexes’ regulation of key cellular activities and response to rapamycin, as well as to 
other rapamycin-derived drugs (rapalogs). We have targeted both mTORC1 and mTORC2 
for hepatocyte-specific deletion during the gestational period of mice, with the goal of 
describing mTORC1 and mTORC2 signaling and its perturbation in the adult mouse 
 v 
hepatocyte. Our model has shown that deletion of RAPTOR, the regulatory associated 
protein of mTOR, and RICTOR, the rapamycin insensitive component of mTOR, in 
mTORC1 and mTORC2 respectively, leads to widespread effects on the hepatocyte 
transcriptome. We have found that a subset of genes responds both to Raptor and Rictor 
knockout, and an analysis of these genes indicates their function in key disorders of the 
liver, such as non-alcoholic fatty liver disease and hepatocellular carcinoma. Bioinformatic 
analysis following hepatocyte RNA sequencing of mTORC1 and mTORC2 knockout mice 
has revealed an unexpected upregulation of genes known to be regulated by these 
respective complexes. We have also found that cross talk exists between both complexes, 
in which the knockout of one yields the activation of the other. We have additionally found 
translationally relevant enrichments following Ingenuity Pathway Analysis (IPA) of RNA 
sequencing data. These results provide a key mechanistic discovery of mTOR signaling 
activity, and allow for a better understanding of the potential physiological effects of 
mTOR inhibition in human patients.   
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CHAPTER 1 
INTRODUCTION 
1.1 mTOR at a glance 
     The mammalian target of rapamycin (mTOR) is a key serine/threonine family kinase encoded 
in humans and other mammals, with significant and tight evolutionary conservation (1, 78). The 
association of mTOR with other proteins, forming mTOR complexes 1 (mTORC1) and 2 
(mTORC2), initiates its associated signaling (1). mTORC1 signaling occurs following the 
binding of Raptor (regulatory protein associated with mTOR) with the HEAT domain of mTOR, 
and mLST8 (mammalian lethal with Sect13 protein 8) binding to the kinase domain of mTOR 
(79, 80, 81). mTORC1 signaling functions as a response to oxygen, growth factors, amino acids, 
and energy, with cellular stress serving as a well-characterized negative regulator of mTORC1 
signaling (78). Common downstream effects of mTORC1 signaling include lipid and nucleotide 
synthesis, protein synthesis, and inhibition of autophagy, all serving to promote cellular growth 
(2, 78).  
      mTORC2, on the other hand, regulates different functions, and was originally discovered due 
to its insensitivity to rapamycin treatment, a mainstay inhibitor of mTORC1 (3). mTORC2 
signaling occurs via the binding of Rictor (rapamycin-insensitive companion of mTOR) to the 
HEAT domain of mTOR, and mLST8 binding to the kinase domain of mTOR (3, 78). mTORC2 
coordinates response to growth factor signaling, and its activation and downstream effectors 
positively regulate cell survival and cell proliferation (78). Specifically, mTORC2 is known to 
regulate Akt, a protein that is frequently dysregulated in particular cancers, and is also 
responsible for actin/cytoskeletal reorganization and protein synthesis (4). Recent basic and 
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translational research has indicated a role of mTOR in the development and progression of 
certain cancers, specifically in a model of hepatocellular carcinoma that demonstrated an 
increase in response towards the chemotherapeutic anti-metabolite 5-fluorouracil upon targeted 
silencing of mTORC1 and mTORC2 (5). Other works have demonstrated development of 
hepatocellular carcinoma in mice with chronic activation of mTORC1 that mirrors that of human 
hepatocellular carcinoma development (6). Additional research has elucidated that a specific 
anti-diabetic drug functions as a preventative measure for mTORC1-mediated liver injury via its 
inhibition of mTORC1 activity (7). Research has additionally focused on Non-Alcoholic Fatty 
Liver Disease (NAFLD), a common finding in the U.S population that affected 75-100 million 
Americans in 2017 (8). Recent work aimed to elucidate the pathogenesis of this syndrome has 
demonstrated that chronic inflammation promotes the progression of the disease, via increases in 
the low-density lipoprotein receptor and phosphorylation of mTOR (9). Besides these results, 
knowledge of the role of both mTORC1 and mTORC2 in regulation of hepatocyte gene 
expression remains limited. 
1.2 The most comprehensive liver specific mTORC2 knockout study  
      One of the two most comprehensive studies on the effects of mTOR perturbation was 
conducted by Lamming et.al. in 2013. Rictor was knocked out using a LoxP/LoxP Albumin-cre 
mouse model. (10). To activate mTOR signaling, mice were unfed overnight for a total of 16 
hours, and then allowed food ad libitum for three hours prior to sacrifice. To identify effects 
attributable to mTORC2 on the hepatic transcriptome, liver extracted from the Rictor KO group 
was compared to liver from wild-type mice (n=4). The comparison was achieved using 
microarray analysis on Affymetrix Genechip Mouse Gene 1.0 ST arrays (10), with a False 
Discovery Rate (FDR) q-value of less than 0.05 showing expression differences in a total of four 
3 
genes between control and Rictor KO (RKO) animals. These genes were the leptin receptor 
(Lepr), insulin-like growth factor binding protein 1 (Igfbp1), and the insulin receptor substrate 2 
(Irs2), all strongly upregulated in RKO animals, with glucokinase downregulated in RKO 
animals(10). In order to confirm that these results were cell autonomous (not due to perturbed 
hormone or nutrient signaling), primary hepatocytes from RKO and WT were cultured and 
harvested for RNA, which yielded concordant increases in expression of Lepr, Igfbp1, and Irs2, 
in RKO cultures as compared to WT. Decreased Gck expression in RKO cultures was observed 
as concordant to decreased expression in RKO mouse liver samples as compared to WT. The 
aforementioned genes are all critical in both cell division and in lipid balance, suggesting a role 
for mTORC2 in regulation of lipid metabolism in the liver.  
    In addition, the Lamming et.al. study used mice that were unfed overnight for 16 hours, and 
then treated with 10-mg/kg rapamycin during feeding in order to inactivate mTORC1. This was 
conducted in order to compare the effects of mTORC2 KO with the effects of mTORC1 
inhibition. This would therefore allow determination of complex-specific changes in hepatic 
gene transcription. Rapamycin administration was additionally decided upon in order to limit the 
activation of mTORC1-related genes that had been noted in a previous experiment (64). The 
liver transcriptome of rapamycin-fed animals was compared to the mTORC2 Rictor KO group 
using a microarray as was done for WT and Rictor KO mice in the previous experiment 
described.  Changes in genes involved in the metabolism and synthesis of cholesterol, as well as 
changes in aldosterone signaling were all observed in rapamycin-treated mice as compared to 
Rictor KO mice (10). Aldosterone is the key human mineralocorticoid, synthesized from 
cholesterol, and functions as the effector molecule in the renin-angiotensin-aldosterone system. 
This system is critical in the regulation of blood pressure, fluid balance, and blood pressure (83).  
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      Notably, no common biological functions or pathways were identified between Rictor KO 
mice and mTORC1 perturbed mice, with the only similarities being three transcription factors 
significantly altered in Rictor KO mice also altered in mTORC1 perturbed mice. This allowed 
for a generalized view of both mTORC1 and mTORC2 signaling, with the results indicating 
dissimilar downstream targets for both complexes.  
     Given that the role of mTOR in both complexes is to phosphorylate and activate downstream 
targets, RKO mice were analyzed with respect to their phosphoproteome as well (10). Three 
control mice and three RKO mice were unfed for 24 hours, and rapamycin was administered 10-
mg/kg for both groups one hour prior to ad libitum access to food, in order to eliminate 
mTORC1-dependent signaling that had been observed in a previous experiment (64). Mice were 
euthanized 45 minutes into the refeeding period, and liver samples were analyzed using a 
western immunoblot. Results showed reduced AKT phosphorylation, as well as reduced PKC𝛼 
phosphorylation, consistent with selective mTORC2 depletion, with reduction of S6K 
phosphorylation confirming mTORC1 inhibition by rapamycin (10). To explore if known 
mTORC1-regulated sites were changed in RKO mice, the above data was compared to a 
previous analysis of rapamycin treatment in mice (64) and to a quantitative analysis of 
rapamycin-sensitive sites in cell lines (65). Results showed that of 144 RKO-associated proteins 
characterized in the current experiment, only one, CAD S1859, an S6K substrate, was previously 
noted as either rapamycin sensitive or mTORC1 regulated (10).  
     In summary, these results showed a detailed view of mTORC2 signaling, indicating that the 
role of mTORC2 in hepatic signaling is complex, and that its effects are not observed to overlap 
significantly with mTORC1. 
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1.3 The most comprehensive liver-specific mTORC1 study 
     The most comprehensive research on mTORC1 signaling in the mouse liver comes from 
Boylan et. al. in 2015. The study design utilized three groups in total, all composed from 
Sprague-Dawley rats: fetal rats, non-proliferating adult rats, and proliferating rats. Fetal rats were 
administered rapamycin via intraperitoneal injection in-situ on embryonic day 19 at a dose of 5 
micrograms and sacrificed on embryonic day 20. Non-proliferating adults (adults whose livers 
were not partially resected) were fasted for 48 hours, fed, and sacrificed 3 hours post re-feeding. 
Proliferating adults underwent a 2/3 hepatectomy and were sacrificed 24 hours later. Rapamycin 
was administered as a peritoneal injection at a dose of 250 micrograms per 100 g body weight 15 
minutes before re-feeding of non-proliferating adults, and one hour before the 2/3 hepatectomy 
on proliferating adults. Analysis of transcriptome product was accomplished by a microarray on 
the Affymetrix Genechip Rat Gene ST 1.0 and Gene Set Enrichment Analysis.  
     Initial characterization of rapamycin inhibition of mTORC1 signaling yielded marked, but 
incomplete, inhibition of S6 phosphorylation. The effect on the mTOR target 4E-BP1 was 
described as significant but small in magnitude, indicating that rapamycin achieves incomplete 
inhibition of mTOR1 signaling in the context of the Sprague-Dawley rat experimental model (1).  
     Transcriptome (RNA product) analysis via Gene Set Enrichment Analysis (GSEA) for the 
three groups indicated discordant activity: non-proliferating adult rats treated with rapamycin 
exhibited a strong upregulation of genes involved in oxidative phosphorylation, with only 
splicesome-associated genes being downregulated. Proliferating rats, induced via the 2/3 
hepatectomy as described above, exhibited an induction of lysosomal metabolism, steroid 
metabolism, and the acute phase response of the immune system, with no KEGG (Kyoto 
encyclopedia of genes and genomes) results yielding downregulation that was statistically 
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significant. Interestingly, fetal rats administered rapamycin exhibited a downregulation of 
lysosomal genes that were upregulated in adult non-proliferating rats. Indeed, fetal rats exhibited 
downregulation in contrast to upregulation for all of the most significantly affected gene sets for 
both non-proliferating and proliferating rats. 
     Analysis of the translatome (protein product) initially showed no changes in polysomes for 
fetal and adult rats treated with rapamycin, and microarray analysis did not show separations 
between rapamycin and control DMSO liver samples, indicating that the effects of rapamycin 
were likely on a small subset of genes. Translational efficiency calculations noted that for non-
proliferating rats, rapamycin administration induced a moderate decrease in translational 
efficiency, while for proliferating adult rats translational efficiency did not change. Fetal rats, on 
the other hand, exhibited a marked increase in translational efficiency upon rapamycin treatment, 
with a total of 53 genes increased that showed an overall dominance of chemokine ligands and 
acute-phase reactants (1).  Translational efficiency calculations for fetal rats, however, showed a 
resistance to rapamycin for the translation of genes with a complex 5’ untranslated region, in 
direct contrast to both adult models, which exhibited rapamycin-mediated inhibition of 
translational activity of complex 5’ UTR genes (1).  
     Overall, the Boylan et. al study notes that there is a significant discord between mTORC1 
signaling in the fetal as compared to the adult liver, with additional discord displayed between a 
non-proliferating and proliferating adult liver. Fetal rats are observed to have a more rapamycin-
resistant phenotype than adult rats, while rapamycin treatment of non-proliferating and 
proliferating animals induced the expression of different genes between groups. This leads to the 
conclusion that mTORC1 activity is not consistent throughout development, and that differences 
also arise in its activity in proliferating and non-proliferating liver tissue. The rapamycin 
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resistance observed in fetal rats was described as a possible mechanistic explanation to 
rapamycin resistance observed in certain cancers. Specifically, it was noted that the 
asynchronous proliferation in the rat fetus represented a cellular condition observed in many 
cancer cells, which could theoretically explain rapamycin resistance in certain cancers. In 
summary, the most notable conclusion from this work revolved around a clear developmental 
and physiologically divergent effect of mTORC1 signaling during different developmental and 
proliferative stages of the rat hepatocyte.   
1.4 A summary of the two key liver specific mTOR knockout studies 
     The above two studies serve as the most recent liver-specific study of mTORC1 and 
mTORC2 signaling perturbations, and with the incorporation of next-generation sequencing, 
allow for visualization of the downstream effects of perturbation in both signaling complexes. 
However, there exists research suggesting a close signaling and regulatory relationship between 
mTORC1 and mTORC2 (11), and taking into account the works of Lamming et. al. and Boylan 
et. al., there still remains a gap in the knowledge of downstream effects of either mTORC1 or 
mTORC2 perturbation, specifically in regards to a pure knockout in contrast to administration of 
rapamycin to achieve mTORC1 inhibition. 
1.5 An overview of mTOR signaling 
      It is known that high cellular energy and growth factor signaling serves as an activator of 
mTORC1 signaling through its positive regulation of PI3K and IRS. This in turn allows for AKT 
activation, which activates mTORC1 via an inhibition of the TSC1/TSC2 complex, allowing for 
RHEB-mediated activation of mTORC1 signaling (46-49). mTORC1 signaling then upregulates 
S6K1, which inhibits PI3K and thus negatively regulates AKT signaling, providing negative 
feedback to mTORC1 activation (49).  
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     While mTORC2 activation is not as well studied (11), it is known that PI3K activation via 
growth factor signaling allows for a catalysis of PIP2 to PIP3, with PIP3 then activating 
mTORC2. Given that mTORC1 activation yields S6K1 transcription, which then negatively 
regulates PI3K, inhibition of mTORC1 may have downstream effects on mTORC2, 
mechanistically occurring via the loss of S6K1 negative regulation of PI3K, thus allowing for 
PIP3-mediated activation of mTORC2 signaling (51-53). Recent research has highlighted the 
role of PI3K in activation of mTORC2, specifically that AKT-independent activation of 
mTORC2 is dependent on PI3K-mediated conversion of PIP2 into PIP3 (12). Earlier research 
additionally established that PIP3 was capable of inducing mTORC2 signaling in cell cultures 
characterized by an AKT knockout phenotype (13). These studies have raised questions on the 
regulation of mTORC1 and mTORC2 signaling and subsequent transcriptome-wide effects, and 
have led us to pursue an experimental design allowing for comparison of gene expression in 
mice that have either mTORC1 or mTORC2 knocked out in utero.   
1.6 Our experimental approach 
     Recent discoveries have noted that mTORC1 signaling changes with age (54). Specifically, it 
was noted that mTORC1 signaling, as measured by the activity of well-characterized targets of 
mTORC1 activity, decreases with age in hepatocytes. In addition, it was found that mTORC2 
signaling in unfed male mice increases with age (54).  Given that mTORC1 responds to growth 
signaling and is a known regulator of cell division and division-critical downstream events, 
studies conducted with immature mice may show effects that are due to a baseline higher level of 
mTORC1 signaling, one that is not normally present in the adult population. To that end, we 
have chosen a model that utilizes fully developed adult mice, to present a view of mTORC1 and 
mTORC2 signaling that is not perturbed due to developmentally related events. This approach, 
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in contrast to the recent approaches taken by Lamming et. al. and Boylan et. al., allows for a 
clean comparison between mTORC1 KO and mTORC2 KO mice, with complete inhibition of 
either signaling complex via Raptor or Rictor knockout achieved during the early stages of 
gestation. This serves to mitigate any of the aforementioned developmentally related changes in 
signaling from affecting the hepatic transcriptome. In addition, this also avoids comparing a 
knockout model to a drug-induced suppression model, thereby maintaining more readily 
comparable data sets and results of mTOR signaling perturbation.  
     Our current work seeks to completely describe the role of mTORC1 and mTORC2 in the 
adult liver metabolism, and to evaluate the effects of knockout on gene expression in adult 
mouse hepatocytes. To our knowledge, studies comparing the effects of knockout of mTORC1 
and mTORC2 specifically in mature mouse hepatocytes have not been conducted with a next-
generation sequencing approach, making our work particularly relevant in understanding the role 
of both mTOR complexes in hepatocytes, particularly for genes that may have been missed with 
previous, non high-throughput analysis. With the evidence presented by the Lamming et. al and 
Boylan et. al studies indicating that there may not much crosstalk between the two complexes, 
we have identified the need to compare mTORC1 KO and mTORC2 KO animals directly, with a 
liver-focused RNA-seq approach to test if this is truly the case.  
     Our present study has found that there are significant differences in gene expression in mice 
with mTORC1 or mTORC2 knocked out, with a particular subset of genes found to be altered 
both in C1 and C2 KO animals. Indeed, a subset of Kegg, Reactome, and Gene ontology 
identities was upregulated both in response to mTORC1 KO and mTORC2 KO, indicating a 
compensatory response from either complex when one or the other is knocked out. We have 
additionally found several unique transcription factors, deemed upstream regulators, which are 
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predicted to be affected by an mTORC1 or mTORC2 KO genotype based on Ingenuity Pathway 
Analysis. These factors allow for us to create a more detailed map of hepatic mTOR signaling, 
and additionally allow for us to make certain translational connections between perturbations in 
mTOR signaling and the progression of hepatocellular carcinoma and non-alcoholic fatty liver 
disease. Together, these results add significant levels of detail to hepatic mTOR signaling, 
elucidate potential clinical implications of mTOR perturbations in the liver, and may explain the 
molecular mechanisms behind hepatocellular carcinoma and non-alcoholic fatty liver disease.  
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CHAPTER 2 
 MATERIALS AND METHODS 
2.1 Mus. musculus model development 
     mTORC1 KO mice were generated by crossing Alb-cre females (Stock No: 003574, The 
Jackson Laboratories) with homozygous floxed mutant mice with LoxP sites flanking exon 6 of 
the Raptor gene (Stock No: 013188, The Jackson Laboratories). The resultant F1 offspring were 
heterozygous for the Raptor flox allele and the albumin-cre transgene. These F1 females were 
then backcrossed with Raptor floxed males, and the offspring F2 generation were genotyped with 
qRT-PCR to identify F2 offspring homozygous for floxed Raptor and heterozygous for Alb-cre 
transgene, with approximately 25% of the F2 generation yielding this genotype. mTORC2 KO 
via Rictor KO were generated utilizing an identical protocol, with the only difference being in 
the first cross, where mice possessing homozygous LoxP sites flanking exon 11 of the targeted 
Rictor gene (Stock No: 020649, The Jackson Laboratories) were used.  
     Following development of the F2 generation, the offspring, hereafter referenced as the F3 
generation, were allowed to develop for 75 days postnatal, and were then euthanized. These 
animals were homozygous for Rictor and raptor deletion, with WT animals lacking Alb-cre 
transgene on the floxed Rictor/raptor sites. Livers of these animals were excised, and following 
completion of liver excision, small samples of the livers of these euthanized animals were taken 
for RNA sequencing. The remaining liver samples were frozen at -81 centigrade storage for 
future analysis.   
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2.2 RNA Extraction 
    RNA extraction was conducted using approximately 1.0 gram of thawed liver tissue 
homogenized with 1.0 mL of TRIzol reagent (ThermoFischer Catalog No: 15596026). The 
homogenized solution was phase separated in 0.2 mL of isoamyl-free chloroform, vortexed, and 
centrifuged at 12,000g for 15 minutes at 4 degrees centigrade. The aqueous layer present in the 
centrifuged tubes was transferred to new centrifuge tubes, mixed with 0.5 mL of isopropyl 
alcohol, and centrifuged at 12,000g under 4 degree centigrade refrigeration to precipitate the 
RNA. Following centrifugation, the supernatant was removed and discarded, and two cycles of 
washing with 75% ethanol were conducted in a ratio of 1 mL ethanol:1 mL TRIzol reagent. 
Following the second wash with ethanol, the RNA precipitate was re-suspended in 100 
microliters of Tris/Borate/EDTA (TBE) buffer, incubated at room temperature for 10 minutes, 
and analyzed for concentration and purity in a Nano-Drop spectrophotometer (Thermo-Fischer 
Catalog No: ND-2000). RNA quality was assessed using an Agilent 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA). All RNA samples were stored at -81 centigrade for further 
downstream analysis.  
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2.3 RNA-Seq Library Preparation 
The plate was removed from -20 degree centigrade storage and thawed to room temperature, 
upon which 2.5 microliters of Resuspension buffer was added to each well plate, along with 12.5 
microliters of A-Tailing Mix. The plate was run on the Bio-Rad CFX384 cycler at 37 degrees 
centigrade for 30 minutes and 70 degrees centigrade for five minutes.  
     To each well was added one unique RNA adapter index, along with 2.5 microliters each of 
Resuspension buffer and Ligation mix. The well plate was run at 30 degrees centigrade for one 
hour in the Bio-Rad CFX384 cycler. Upon completion, 5 microliters of the Stop Ligation Buffer 
was added to each well plate immediately.  
     42 microliters of AMPure XP beads were added to each well plate, and incubated at room 
temperature for 15 minutes. The plate was then placed on the magnetic stand for five minutes, 
and the supernatant was discarded. 200 microliters of 80% ethanol was added to each well and 
removed following 30-second incubation. This was repeated for a total of two washes. The plate 
was then allowed to dry on the magnetic stand for 15 minutes, upon which the plate was 
removed from the stand and to it was added 52.5 microliters of Resuspension Buffer. The plate 
was incubated for two minutes, placed on the magnetic stand for five minutes, and the 50 
microliter supernatant from each well plate was transferred to a new well plate. To this was 
added 50 microliters of AMPure XP Beads, upon which the plate was incubated for 15 minutes 
and for a further five minutes on the magnetic stand. The supernatant was removed, and 200 
microliters of 80% ethanol was used for two washes as described above. Following washing, 
22.5 microliters of Resuspension Buffer was added to each well plate, the plate was incubated on 
the magnetic stand for five minutes, and the 20 microliters of the supernatant from each well was 
transferred to a new well of the plate.  
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     Five microliters of PCR Primer Cocktail were added to each well with the supernatant, along 
with 25 microliters of the PCR Master Mix. The plate was run in the Bio-Rad CFX384 cycler for 
one cycle at 98 degrees centigrade for 30 seconds, 15 cycles at 98 degrees centigrade for 10 
seconds, 60 degrees centigrade for 30 seconds, 72 degrees centigrade for 30 seconds, and 72 
degrees centigrade for five minutes.  
     Following PCR amplification, 50 microliters of AMPure XP beads was added to each well, 
and the plate incubated at room temperature and on the magnetic stand for a total of 20 minutes. 
The supernatant was removed, and 200 microliters of 80% ethanol was used for two washes as 
described above. The wells were incubated on the magnetic stand for 15 minutes, and removed, 
upon which 32.5 microliters of Resuspension Buffer was added to each well of the plate. The 
plate was then incubated on the magnetic stand for five minutes, and 30 microliters of the 
supernatant was transferred to centrifuge tubes and stored for further downstream analysis.  
2.4 RNA-Seq 
     RNA-seq was conducted utilizing an adapted protocol from Illumina. High-throughput 
sequencing was performed using a NextSeq500 sequencing system (Illumina) in the Genomic 
Resource Laboratory of the University of Massachusetts, Amherst. Complementary DNA 
libraries were single-end sequenced in 75 cycles using the NextSEquation 500 High Output Kit 
(FC-404-1005; Illumina) in a multiplex run of twenty discrete samples.   
RNA-seq was conducted for n=3 samples per group (Control WT or Control KO) for the 
mTORC1 experiment and n=4 samples per group for the mTORC2 experiment. For mTORC1, 
the average number of reads was 38.8 million reads per sample, with the average percentage of 
reads aligned to the reference genome (mm10) being 90.2%. For mTORC2, the average number 
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of reads was 26.3 million reads per sample, with the average percentage of reads aligned to the 
reference genome (mm10) being 84.7%. 
2.5 Western Immunoblotting 
     Western blotting was conducted using Thermo-Fischer Scientific Kit Numbers 78510 and 
23225/23227 and an adapted protocol from Thermo-Fischer Scientific (Pub. No. MAN0011386). 
Unless otherwise indicated, all materials and kit numbers are from the above.  
     Protein was extracted using T-PER reagent with added protease inhibitor, in a ratio of 
approximately 100 mg liver tissue to 2 mL of prepared T-PER reagent. This mixture was 
homogenized at 10,000g until tissue was completely ruptured. The supernatant was collected and 
isolated into 100 microliter aliquots. 
     Sample quantification was completed following a standard curve preparation, using an 
albumin standard (BSA) for the curve preparation. The standard curve was prepared according to 
the manufacturer’s instruction (Thermo-Fischer Scientific Kit 23225/23227). 
     Specimen was prepared in a solution of 4X Laemmili Buffer dye diluted 9:1 with 9 parts 
Laemmili Buffer and 1 part beta-mercaptoethanol. A standardized amount of protein was added, 
with buffer added in a ratio of 1 part buffer dye to 3 parts sample. This mixture was boiled for 
five minutes on a thermo-cycler and cooled on ice for five minutes. 
     Gel loading was done with Tris-glycine SDS as a running buffer, and the gel was run at 50V 
until migration out of the wells was observed, at which point the gel was run at 100V for 
approximately one hour. 
     Gel transfer was accomplished with the use of nitrocellulose membrane, with the membrane 
placed in transfer buffer for 10-15 minutes. The transfer buffer consisted of a mixture of 100 mL 
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methanol, 100 mL of running buffer, and 800 mL of deionized water. Transfer was done on ice 
with a running voltage of 15V for overnight. 
Blocking was done with a solution of 3% blotting-grade skim milk for one hour at room 
temperature, and primary antibody targeting was completed in 3% blotting-grade skim milk 
overnight at 4 degrees centigrade. Secondary antibody incubation (Abcam Cat. No: ab6721) in a 
solution of 3% blotting-grade skim milk, was conducted following 5 rinses with 1X TBS-T 
buffer (100 mL 10X TBS, 900 mL deionized water, 2 mL of Tween-20), for 45-60 minutes. The 
blot was illuminated with Pierce ECL Western Blot Substrate (Thermo-Fisher Cat. No: 32106) 
and scanned with a Syngene G:BOX F3 scanner at the Department of Veterinary and Animal 
Sciences at the University of Massachusetts, Amherst. 
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2.6 Analysis of RNA-Seq data 
To analyze the data from our mRNA sequencing experiment, read filtering, trimming, and de-
multiplexing were performed via the BaseSpace cloud computing service supported by Illumina 
(available at: https://basespace.illumina.com/home/index). Furthermore, the preprocessed reads 
were mapped to the reference mouse genome (MM10) using the TopHat2 aligner (14). Aligned 
reads were then used for assembly of transcripts using Cufflinks, version 2.1.1, and differential 
expression of reference transcripts using Cuffdiff, version 2.1.1 (15). Differential expression data 
sets were further used for gene set enrichment analysis (GSEA, Broad Institute, Boston, MA; 
available at: www.broadinstitute.org/gsea).  
     Following completion of RNA-seq, bioinformatic analysis using Metascape, Gene Set 
Enrichment Analysis, and Ingenuity Pathway Analysis (IPA) was conducted (16, 17, 66). 
Metascape was conducted using default settings. RNA-seq data meeting a q-value of 0.05 or 
below was selected for further analysis. A list of genes found in the raw data for mTORC1 and 
mTORC2 KO that demonstrated statistical significance was taken and analyzed via Metascape. 
This list is hereafter referred to as the RNA-seq shortlist for both mTORC1 and mTORC2.  Gene 
Set Enrichment Analysis was conducted using default settings (16), and cutoff values were 
assigned as a normalized enrichment score (NES) of >1.70 and a false discovery rate (FDR) 
value q<0.1. IPA was conducted using default settings, utilizing the aforementioned RNA-seq 
shortlist. Figures of canonical and disease pathways for knockout groups, as well as upstream 
and downstream analysis were generated through the use of IPA (QIAGEN Inc., 
https://www.qiagenbio- informatics.com/products/ingenuity-pathway-analysis). 
     GSEA was conducted using the Hallmark, C2, C3, and C5 collections of gene sets. 
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Hallmark is a collection of discrete gene sets computationally generated from the overlap of 
multiple “founder” gene sets for a particular biological process. The genes present in overlap are 
defined as having coherent expression, and are combined together to create a discrete Hallmark 
gene set (96).  
     C2 is a collection of gene sets that is curated from multiple sources, including online pathway 
databases and biomedical literature.  
     C3 is a collection of gene sets that represents targets of transcription factor or microRNA 
regulation, with each set containing genes that are grouped by short sequence motifs that are 
conserved in their non-protein coding regions.  
     C5 is a collection of gene sets that are derived from gene ontology annotations. The gene sets 
in this collection are based on specific gene ontology terms and belong to one of the three 
following categories: Molecular Function, Cellular Component, and Biological Process. Gene 
ontology terms that yielded very broad categories with very large gene sets were eliminated, as 
were terms that produced gene sets with fewer than five genes in total. 
 All gene collection sets that yielded results in line with the cutoff values described above are 
discussed in the results section. 
     Following GSEA analysis, a comparison of mTORC1 KO and mTORC2 KO data sets 
revealed a subset of genes that were changed both in mTORC1 KO and mTORC2 KO animals. 
These genes were additionally visualized using Metascape.  
   In the next step of our analysis, we used the aforementioned collection of genes that were 
differentially expressed in both mTORC1 KO and mTORC2 KO animals for a functional 
analysis. These genes were identified from the raw data for statistically significant (FDR q value 
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<0.05) gene expression changes, and genes that appeared in both the mTORC1 KO list and the 
mTORC2 KO list were included as differentially expressed for both mTORC1 and mTORC2.  
 We used IPA in order to visualize the activity of upstream regulators that were most likely 
leading to the changes in gene expression that we saw in our RNA-seq shortlist data. Following 
this analysis, we were able to construct a map of mTORC1 and mTORC2 signaling through 
these regulators, and were able to visualize what the predicted states of these regulators would be 
in a knockout genotype of either complex. We then utilized STRING (84) in order to illustrate 
protein-protein interactions amongst the regulators that were found in our IPA upstream analysis 
results. Following this, any upstream regulator that did not have a known interaction with other 
regulators in the list was selected for a literature review in PubMed. This was conducted 
separately for mTORC1 and mTORC2 upstream regulators, using the key words “regulator 
name” and “liver” or “hepatocellular carcinoma” or “mTOR” or “mTORC1” or “mTORC2” or 
“function.” 
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CHAPTER 3 
 RESULTS 
3.1 Confirmation of mTORC1 and mTORC2 KO: RNA-seq results and western 
immunoblot of mTORC1 and mTORC2 liver samples 
     To confirm that our knockout model succeeded, we performed western immunoblotting for 
mTORC1 and mTORC2 wild-type and KO liver cell lysates. We additionally analyzed our 
RNA-seq data for the direction of expression change in Raptor and Rictor, respectively. As was 
expected, knockout of Rictor in mTORC2 experiment mice yielded complete absence of 
phosphorylated AKT, a target of mTORC2 signaling (Figure B.5). mTORC1 results similarly 
showed severely reduced amounts of phosphorylated p70S6K, a target of mTORC1, as compared 
to control. However, there remained a small amount of phosphorylated pP70S6K in the blot, 
indicating that Raptor knockout almost completely abrogated phosphorylation of p70S6K, but 
did not fully abolish it (Figure B.5). In addition, we found that both Raptor and Rictor were 
downregulated in our RNA-seq shortlist data, as shown in Figure B.5. These results are further 
elaborated upon in the discussion portion of this manuscript. 
3.2 Genes Differentially Expressed in the mTORC1 KO Experiment: 
 For mTORC1, Figure B.1 shows significant enrichment for multiple gene functional groups, 
with the highest enrichment shown for steroid metabolic process, response to stilbenoid, 
monocarboxylic acid metabolic process, and mitotic cell cycle. The  –Log10(P) value indicates 
the likelihood that a shown enrichment is due to chance, with a more negative value indicating 
that the enrichment is very unlikely due to chance alone (18).  mTORC1 is known to play a main 
role in growth signaling regulation, cell division activity, and nutrient abundance (1), so the 
knockout of this complex would explain enrichment in genes involved in these same processes.  
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     Figure B.1 additionally shows that regulation of wound healing and responses to chemokines 
are enriched, both which are functions of the innate immune system (55). With a significant 
amount of mTORC1 focused research and review describing immune-mediated effects (56, 57), 
we did not find it unexpected to note immune-related gene enrichments following a perturbation 
of mTORC1 function.  
It is important to note that the enrichment found in Metascape analysis does not indicate 
direction of gene expression change, that is, it is not possible to say from Metascape 
visualization alone if gene expression is being up or downregulated. Therefore, further 
downstream analysis was conducted for both complexes in order to better understand gene 
expression changes. 
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3.3 Genes Differentially Expressed in the mTORC2 Experiment 
     For mTORC2, Figure B.2 shows significant enrichment for genes involved in the 
monocarboxylic acid metabolic process, the monocarboxylic acid biosynthetic process, 
regulation of small molecule metabolic process, and triglyceride metabolic process. With 
mTORC2 known to be an activator of Akt1, as well as PKC and SGK (4), effects on metabolic 
processes and synthesis of triglycerides, both important for cellular activity as well as for core 
cellular functions (58), is an expected finding in an mTORC2 knockout genotype. 
     Surprisingly, we noted enrichments in genes responsible for monocyte differentiation, cell 
chemotaxis, neutrophil degranulation, and positive regulation of NIK/NF-kappaB signaling. 
These functions are all well-known responses that define both an innate and an adaptive immune 
response (60). However, most research to date has implicated mTORC1 as a known activator of 
NFkB signaling (59), so an observed enrichment of these mTORC1-implicated functions in an 
mTORC2 knockout genotype was an unexpected result. Chemokine enrichment was also 
observed in Figure B.1, following mTORC1 perturbation, with chemokines functioning as cell 
attractants in innate as well as in adaptive responses (55, 60). Neutrophil degranulation is well-
conserved, innate immune system mediated regulator of cytotoxicity (60), and its observed 
enrichment following mTORC2 knockout was an additional interesting observation.   
     As for mTORC1 knockout, Metascape analysis only shows enrichment and does not indicate 
upregulation or downregulation of gene expression. Therefore, the immune-related results above 
do not point to positive or negative regulation of the respective immune functions, but indicate 
that changes in these functions occur in mTORC2 knockout animals. These results, along with 
mTORC1 knockout results, are explored further in the following sections. 
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3.4 RNA-seq data yields a list of commonly enriched genes in both groups 
     There were a small number of genes that were either not specifically referenced in the 
literature, did not exist in humans, or did not have any known function/literature related to their 
roles in hepatocellular carcinoma (HCC), liver/hepatocyte function, or NAFLD. These genes 
were Lect1 and Clec2h. Lect1 did not have any articles related to liver, HCC, or NAFLD. 
Clec2h, while shown to be upregulated in male and female offspring of mice fed a Western high 
cholesterol, high fat diet (19), has no human ortholog, and these two genes were not pursued 
further due to lack of translational relevance. The total number of translationally relevant genes 
identified, therefore, was 21, as summarized in Table A.1. A comparison of the total number of 
genes changed in mTORC1 KO and mTORC2 KO, along with the aforementioned commonly 
changed genes, is shown in a Figure B.4. 
     A summary of the known functions of the protein product of each of the 21 genes found to be 
changed in mTORC1 and mTORC2 KO mice was adapted from the NCBI (National Center for 
Biotechnology Information) database, and is shown Table A.1.  
     Following the determination of a list of 21 genes found to be perturbed in both mTORC1 KO 
and mTORC2 KO experimental groups, a search in PubMed was conducted using the key words: 
‘gene x’ or ‘gene x and liver’ or gene x and hepatocellular carcinoma’ or ‘gene x and Non-
Alcoholic Fatty Liver Disease (NAFLD).’ The identifier gene x refers to any of the 20 genes, as 
this search was conducted identically for all genes in the list. No limit was placed on the year of 
publication, and no language limits were applied. 
     Following the identification of the 21 genes found to be perturbed in both mTORC1 KO and 
mTORC2 KO experimental groups, results in the literature were separated into three groups as 
follows: hepatocellular carcinoma/liver cancer, NAFLD or fatty liver, and related 
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diseases/human morbidities. These three groups are presented in Table A.1. A detailed 
annotation of each gene is presented in Appendix C of this manuscript.  
3.5 An analysis of genes affected in both KO groups 
     For the shortlist of genes responding to both mTORC1 and mTORC2 KO, Metascape analysis 
showed strong enrichment of genes involved in the monocarboxylic acid metabolic process, as 
well as in other lipid metabolic processes (Figure 1.c) 
An overview of the 23 genes found to be responding both to mTORC1 and mTORC2 KO was 
created as described in the methods section. This is found in Figure B.3. Interestingly, the results 
show similar enrichment that was found in mTORC1 and mTORC2 knockout groups using 
Metascape analysis, as visualized in Figures B.1 and B.2. These results, in addition to the gene 
set enrichment analysis results, are discussed at length in the discussion portion of this 
manuscript.  
3.6 Gene Set Enrichment for mTORC1 and mTORC2 KO groups 
3.6.1 mTORC1 
     GSEA results that met our cutoff values included the Hallmark collection of gene sets, C2 
collection of gene sets, and the C5 collection of gene sets.  
     Hallmark results showed a negative enrichment for genes involved in Bile Acid metabolism, 
as well as in xenobiotic metabolism and cholesterol homeostasis. Positive enrichment was shown 
for genes involved in E2F and G2M targeting, as well as in allograft rejection and immune-
inflammatory signaling. These are visualized in Table A.2. 
     Upon a further exploration of both bile acid metabolism as well as cholesterol homeostasis, 
we found that the activity of both of these processes is linked, with bile acid signaling via G-
Protein coupled receptors critical for regulating hepatic glucose and lipid homeostasis, and 
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cholesterol catabolism to bile a key component of tight cholesterol homeostasis (60). Notably, 
the activity of both of these processes is known to be regulated in an enterohepatic circuit, with 
Akt/mTOR activity a key regulator of the aforementioned circuit (60).  
     E2F and G2M targeting both refer to cell cycle checkpoint targeting, with mTORC1 
activation known to be a positive regulation of cell division and cell growth (1). However, our 
results noted strong positive enrichment targeting of the cell cycle, indicating that mTORC1 
knockout promoted cell cycle progression, the opposite of what would be expected. Notably, 
allograft rejection and immune-inflammatory signaling were positively enriched in mTORC1 
knockout mouse hepatocytes, an unusual result as well given the known roles of mTORC1 both 
in tissue rejection as well as in immune related inflammation (1,62,63).  
     C2 collection results showed a negative enrichment for Reactome and Kegg (Kyoto 
Encyclopedia of Genes and Genomes) pathways involved in cholesterol biosynthesis as well as 
in gene expression activation via Srebf. Positive enrichment was shown for Reactome pathways 
involved in translational and transcriptional activity, as well as in rRNA processing, cell division 
activity, and response to influenza infection. These are visualized in Table A.3. 
     As was observed for Table A.2, positive enrichments were for cellular processes that are 
regulated by mTORC1, an unexpected finding given that mTORC1 knockout should have 
theoretically suppressed these categories. Subsequent gene ontology analysis using the C5 
collection of gene sets, visualized in Table A.4, showed positive enrichment for genes 
functioning in ribosomal synthesis and bioactivity, as well as in genes functioning in cell 
division, protein localization, and regulation of lymphocyte migration. As was observed in 
Tables A.2 and A.3, the knockout of mTORC1 yielded an unexpected positive enrichment for 
functions that were predicted to be negatively affected by mTORC1 perturbation.  
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3.6.2 mTORC2 
     C2 results showed positive enrichment for Reactome pathways involved in ribosomal activity, 
rRNA processing and activity, as well as in DNA processing activity. Interestingly, positive 
enrichment was observed for response to influenza infection, as was shown in Table 2.a for 
mTORC1 KO. Additional similarity in results to mTORC1 was displayed for rRNA processing, 
nonsense-mediated decay, and selenoamino acid metabolism. All of the C2 mTORC2 KO results 
are detailed in Table A.5. 
     C5 results showed positive enrichment for genes functioning in ribosomal activity and protein 
localization. These overlapped with C5 results for mTORC1, with the highest enrichment values 
for the C5 collection being cytosolic ribosome gene ontologies for both mTORC1 and mTORC2 
groups. These results are detailed in Table A.4 for mTORC1 and Table A.6 for mTORC2.  
3.7 Common Enrichments in mTORC1 and mTORC2 KO groups    
     GSEA results yielded a set of enrichments terms that were positively enriched both in 
mTORC1 KO and mTORC2 KO mice. These results are detailed in Table A.7. Interestingly, 
positive enrichment was observed for KEGG pathways, Reactomes, and Gene Ontologies that 
would have been expected to have a negative enrichment upon mTORC1 or mTORC2 knockout. 
Following this observation, we conducted follow-up work to uncover both the identities of genes 
that are changed in both mTORC1 and mTORC2 KO animals.  
     To add to the observations in Table A.7, we compiled a datasheet (data not shown) in order to 
gain an understanding of the identities of each gene changed in the enriched categories in Table 
A.7. The results in this dataset show that almost all of the genes enriched in both mTORC1 and 
mTORC2 KO animals are genes belonging to the ribosomal large and small subunits. Indeed, 
these results are consistent even in categories that initially may not appear to be centered on 
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ribosomal activity, such as Reactome_Influenza_Infection and 
Reactome_Selenoaminoacid_Metabolism.  
3.8 Ingenuity Pathway Analysis of mTORC1 and mTORC2 KO Groups 
3.8.1 mTORC1 KO results 
     In order to completely describe mTORC1 signaling, we first visualized impacts of mTORC1 
KO in respect to core cellular functions and to common disease states of an organism. As 
visualized in Figure B.6, strong negative enrichments are observed in pathways responsible for 
the synthesis of cholesterol, as well as for activation of LXR/RXR and FXR/RXR, the former 
known to regulate cholesterol biosynthesis as well. The only positively enriched category out of 
the top 15 enriched categories was the Sirtuin signaling pathway, an interesting finding whose 
translational aspects is elaborated upon in the discussion portion of this manuscript.  
      In regards to the top 15 disease categories enriched in mTORC1 KO animals, the highest 
enrichments were observed for lipid metabolism, small molecule biochemistry, and vitamin and 
mineral metabolism, as shown in Figure B.7. Additional enrichments were observed for 
metabolic disease, organismal injury and abnormalities, cell death and survival, and endocrine 
and gastrointestinal disease. All enrichments were well above the threshold value, as shown by a 
p-value of less than 0.05.  
3.8.2 mTORC2 KO results 
     In contrast to mTORC1 KO data, mTORC2 KO showed significant enrichments in the top 15 
categories of cellular canonical pathways, but did not show direction of enrichment, as shown in 
Figure B.8. Indeed, two of the top 15 canonical pathways shown did not have any activity data 
available. This may be a result of the limited research on mTORC2 as compared to mTORC1, 
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leading to the mTORC2 associated pathways not being as well studied or even identified, as are 
associated pathways.  
     For disease pathways enriched with mTORC2 KO, lipid metabolism was a top enrichment, as 
it was for mTORC1 KO. Additional similarities were observed in small molecule biochemistry 
enrichment as well as in organismal injury and abnormalities and gastrointestinal disease. 
Unique categories were for hepatic system disease as well as for metabolic disease, with all 
enrichments detailed in Figure B.9. P-values were similarly well below threshold as they were 
for the mTORC1 KO data, indicating statistical significance of findings.  
3.9 mTOR Upstream Regulator analysis 
3.9.1 mTORC1 KO Results 
     Following the general findings afforded to us by the canonical and disease pathway analysis, 
we utilized the same shortlist from mTORC1 KO RNA-seq data in order to describe the 
regulators of the genes that were altered in the shortlist data. These results were sorted based on 
the type of upstream regulator, with our analysis focusing on transcription regulators and ligand-
dependent nuclear receptors. This analysis included the predicted activation score; a calculated 
value based on the activation z score, which was calculated from the activation states of the 
target molecules found in our RNA-seq shortlist dataset. In the knockout genotype, upstream 
regulators that were predicted to be inhibited included PPARA, SREBF1 and SREBF2, as well 
as other upstream molecules such as TRIM24, HOXA10, MAF, and STAT5B. 
In the same dataset, upstream regulators that were activated included RARA, CREB1, E2F3, 
NFKB2, and JUN, among others. These results are summarized in Figure B.10, and the roles of 
these various factors are all described in the discussion section of this manuscript. 
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3.9.2 mTORC2 KO results 
     For mTORC2 KO data, an identical protocol was followed for generation of the list of 
upstream regulators as for mTORC1 KO. In this dataset, there were no positive upstream 
regulators that met a p-value of 0.05 or lower, and there were overall significantly fewer 
upstream regulators found that met statistical significance than were found for mTORC1 KO 
data. However, there was one upstream regulator, STAT5B that was predicted to be negatively 
activated in this data set as well as in the mTORC1 KO data set. This is shown in Figure B.11. 
Additional upstream regulators that were predicted to be negatively regulated included PPARD, 
RORA, and MLX, among others. The roles of these factors are all described in the discussion 
section of this manuscript.  
3.10 STRING Analysis for Upstream Regulator results 
3.10.1 mTORC1 results 
     mTORC1 STRING analysis generated a total of three upstream regulators that had no 
predicted interaction with one another and/or with any of the remaining upstream regulators.  As 
visualized in Figure B.12, these three were Sirt2, Hoxa10, and Kdm5b. The role of each gene 
was determined via a literature search in PubMed, and the results and implications are elaborated 
upon at length in the discussion portion of this manuscript.  
3.10.2 mTORC2 results 
     mTORC2 String analysis generated a total of five upstream regulators that had no predicted 
interaction with one another and/or with any of the remaining upstream regulators. As visualized 
in Figure B.13, these five were Etv5, Rora, Ppard, Mlx, and Zbtb20. The role of each gene was 
determined via a literature search in PubMed, and the results and implications are elaborated at 
length in the discussion portion of this manuscript. 
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3.11 mTOR Downstream Signaling Analysis 
3.11.1 mTORC1 KO results  
     Following the determination of the activity of genes that are known regulators of our 
mTORC1 KO shortlist genes, we constructed a signaling pathway based on these data, with 
mTORC1 at the center, in order to show how each regulator interacts with each other, and the 
role of mTORC1 in the signaling mediated through these different regulators. This pathway is 
shown in B.14, with red indicating negatively regulated, and green indicating positively 
regulated. As is visible in the pathway, mTORC1 KO promotes the activation of SREBF2, the 
inhibition of CREB, and the inhibition of activated SREBF1. From these three molecules, 
downstream effectors are either activated or inhibited. These effects are most likely responsible 
for the activation states of the genes in our mTORC1 KO RNA-seq shortlist.  
3.11.2 mTORC2 KO results  
     In the same manner as was done for mTORC1 data, we constructed a signaling pathway, with 
mTORC2 at the center, in order to demonstrate how each regulator interacts with each other. 
This pathway is shown in Figure B.15, with white indicating an indirect connection between the 
two genes, and green indicating positive regulation. Importantly, there is an indirect connection 
between mTORC2 and SREBF1, through which the remaining downstream entities, shown in 
green, are activated. This indirect relationship is likely due to the overall lack of knowledge  data 
of mTORC2 downstream targets as compared to mTORC1.  
  
31 
CHAPTER 4 
DISCUSSION 
4.1 Overview 
     Much research has been devoted to the elucidation of mTOR signaling, with a majority of 
research focusing on the role of mTORC1 due to its aforementioned modulation by the 
immunosuppressant drug rapamycin. However, the role of mTORC2 is not as well described and 
the role of mTORC1 and mTORC2 in concert has yet to be elucidated. As mentioned in previous 
sections, the most recent research from Lamming et.al and Gruppuso et.al have not used a model 
with a liver specific knockout of mTORC1 and mTORC2 from gestation. We have also not seen 
a complete bioinformatic analysis of transcriptome product from these aforementioned liver-
specific knockout mice, and as such noted the existence of incompleteness in the scientific 
literature in respect to liver-specific mTOR signaling describing both mTORC1 and mTORC2. 
     In order to describe mTOR signaling in the manner set forth in the above section, we utilized 
the latest developments in next-generation bioinformatic analysis in order to achieve our results. 
Through the use of RNA-seq followed by analysis with Metascape, GSEA, and IPA, we have 
been able to describe mTOR signaling in the liver with a level of depth that has been lacking in 
the current literature. Our discussion of our results is presented in the following sections. 
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4.2 mTORC1 and mTORC2 KO yields a list of commonly altered genes 
      As shown in Table A.1, our initial RNA-seq data yielded a list of genes that were altered in 
both mTORC1 KO and mTORC2 KO groups. Furthermore, we found that all 21 of these genes 
that were found to have translational relevance had a known role in NAFLD, HCC, or a related 
human morbidity. These results are significant due to the common usage of rapamycin and its 
related rapalogs for immunosuppressive purposes. The changes in these genes and their role in 
human disease indicates that certain side effects of rapamycin treatment may extend to changes 
in transcription of genes that are unrelated to the therapeutic use of the drug. This information 
will likely prove vital to further translational study of the long-term effects of rapamycin 
treatment by providing particular markers of transcriptional change. Additionally, since these 
genes were changed in perturbation of both mTORC1 and mTORC2, there is now additional 
evidence that both complexes regulate multiple different genes. This is important for the 
understanding of how complex diseases such as hepatocellular carcinoma and non-alcoholic fatty 
liver disease progress, and provides a more detailed overview of the signaling that may be 
responsible for disease progression.  
4.3 Bioinformatic analysis of mTORC1 and mTORC2 KO data 
     Our work has shown that the knockout of mTORC1 and mTORC2, respectively, leads to both 
expected and unexpected changes in the mouse liver transcriptome. In addition, we found that 
there were changes in genes responsible for ribosomal biogenesis upon knockout of mTORC1 
and mTORC2, indicating that signaling from both mTOR complexes is likely responsible for 
ribosomal biogenesis.  
     Interestingly, results from Metascape analysis of mTORC2 KO data showed that there were 
enrichments in immune system-related functions, which has until now been known to be 
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regulated by mTORC1 signaling. As shown in Figure B.1, these changes were an unexpected 
finding due to their known association with mTORC1 signaling. Since the ubiquitous mTORC1 
inhibitor rapamycin is used as an immunosuppressant, the regulation of certain immune system 
functions by mTORC2, as suggested by our data, may help explain cases of resistance to 
rapamycin therapy, and may open the field to research on mTORC2 inhibition for particular 
immune system disorders. 
     Further analysis with GSEA revealed additional unexpected findings of mTOR signaling 
perturbation. As shown in Table A.2, mTORC1 KO leads to an upregulation of gene sets known 
to function in cell division as well as in allograft rejection and innate immune response activity. 
These results were the opposite of what was expected.  Given that mTORC1 is known to regulate 
these same functions, we expected a knockout of this complex to lead to a downregulation of 
these functions. These data provide a view of mTORC1 signaling that has not been previously 
described, and these findings suggest that there are likely other signaling complexes that regulate 
mTORC1-dependent functions.  
     In addition, we have found that there is a subset of gene ontology results for mTORC1 KO 
and mTORC2 KO that are similarly enriched, with positive upregulation of gene ontologies that 
would have been expected to be negatively regulated upon mTORC1 or mTORC2 knockout. 
These results, as detailed in Table A.7, show common enrichments of gene ontologies for both 
knockout genotypes, with a positive enrichment shown for all. These results indicate that in 
knockout of either complex, ribosomal biogenesis, DNA repair, and certain immune functions 
are all enriched. Given that the current research suggests that mTOR signaling controls these 
processes, we expected that a knockout would have suppressed these functions.  
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     A more detailed look reveals that the individual genes that compose each enrichment ID 
category were ribosomal protein genes. Therefore, even categories such as 
Reactome_Influenza_Infection and Reactome_Selenoamino_Acid_Metabolism were all 
composed of ribosomal proteins. Ribosomes were likely formed during the period of humanity’s 
Last Common Universal Ancestor (LUCA), and they are necessary for translating all mRNA into 
protein (85-87). Therefore, ribosomes are critical for sustaining life itself, as protein products 
function in heterogeneous roles spanning development, cell division, cell death, cell 
differentiation, defense and immunity, and cell signaling. Signaling from mTORC1 is known to 
regulate aspects of cell division, and mTORC2 signaling is known to regulate cell proliferation 
(1), with ribosomes being key for protein translation that regulates these processes. Therefore, an 
increased enrichment in ribosomal proteins in response to both mTORC1 and mTORC2 
knockout likely indicates that there are compensatory mechanisms in place that maintain key cell 
functions even in the absence of mTOR signaling.  
     Additional support for our findings comes from Western immunoblots, shown in Figure B.5. 
We found that upon knockout of Raptor, the phosphorylation of p70S6K was significantly 
reduced to almost non-existent levels, while a corresponding rise was seen in the amount of 
phosphorylated AKT, a known target of mTORC2 signaling. This type of compensatory 
response was seen in the mTORC2 experiment group as well, with a knockout of Raptor leading 
to abrogated phosphorylation of AKT, while yielding a smaller, but still noticeable increase in 
phosphorylated p70S6K as compared to controls. This gives further credence to our observation 
that abrogation of one complex’s activity brings about increased signaling through the other. We 
have yet to see any mention in the literature of a compensatory increase in liver-specific 
mTORC1 or mTORC2 signaling following the knockout of one of the two complexes, and our 
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results show that there is likely cross-talk between mTORC1 and mTORC2. This finding may 
have translational relevance as well, as rapamycin, an mTORC1 inhibitor, is frequently used as 
an immunosuppressant following organ transplantation as well as in exploratory uses against 
certain forms of cancer. Understanding that the targeted silencing of one mTOR complex may 
bring about increased signaling of the other complex is critical for explaining off-target drug 
effects, cellular proliferation, and other related changes that may occur. While it is currently 
unknown specifically what effects arise following an upregulation of one mTOR complex 
following the inhibition of the other, further studies are needed to explore this unique, liver-
specific mTOR signaling relationship.  
4.4 IPA analysis reveals potential translational implications of liver-specific mTOR 
inhibition 
Two very significant causes of human morbidity and mortality are non-alcoholic fatty liver 
disease, also known as non-alcoholic hepatosteatosis, and hepatocellular carcinoma (HCC) (67-
71). For HCC, treatment options and prognosis for non-resectable disease consist of hepatic 
arterial infusion chemotherapy, radiation therapy, and the multi-kinase inhibitor sorafenib (73, 
74). However, overall survival for metastatic, non-resectable HCC was increased to only 10.7 
months with sorafenib treatment as compared to 7.9 months with placebo (73). While there has 
been a recent clinical trial that has described some benefit of administration of the multi-kinase 
inhibitor regorafenib following sorafenib therapy (75), clinical outcomes for advanced HCC 
remain poor.  
     Recent research has suggested that the sirtuin signaling pathway may mediate poor outcomes 
of sorafenib therapy, specifically via the SIRT1 deacetylase, a key human sirtuin (76). A 
previous study has noted that overexpression of SIRT1 is associated with a poor response in 
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HCC (77).  The role of SIRT1 in HCC is not completely understood, however, research suggests 
that SIRT1 plays a role in HCC progression by regulating the activity of other key oncogenic 
proteins, thereby promoting cancer progression (77). Therefore, SIRT1 may be a significant 
biomarker of HCC progression, and remains an important research target towards sorafenib-
resistant HCC. 
     Our IPA results have shown that the sirtuin-signaling pathway is significantly upregulated in 
mTORC1 KO mice (Figure B.6). The most recent research on SIRT1 and HCC has shown 
downregulation of mTORC1 phosphorylation following treatment of HCC cell lines with 
sorafenib, indicating that sorafenib has an inhibitory effect on mTORC1 in HCC (76). Since 
SIRT1 is implicated in sorafenib resistance in advanced HCC, it is interesting that mTORC1 
inhibition was induced by sorafenib treatment in this research, particularly because our work has 
shown sitruin signaling enrichment following mTORC1 knockout. This may explain the eventual 
decline of patients treated with sorafenib, possibly occurring via a sorafenib-induced 
downregulation of mTORC1. Following this downregulation, there may be an associated 
increase in sitruin signaling that we observed in our results. This may then mediate increased 
SIRT1 transcription and activity, and the subsequent resistance to sorafenib treatment. While 
these research findings are preliminary, they suggest an important link between mTORC1, the 
sitruin signaling pathway, and sorafenib resistance in advanced HCC. More research would be 
needed in order to further elucidate the mechanisms of resistance, as well as possible secondary 
targets for sorafenib-resistant HCC.  
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4.5 IPA reveals a subset of novel downstream effectors of mTORC1 and mTORC2 
signaling 
4.5.1 mTORC1 results 
     IPA analysis allowed for a clearer picture of mTORC1 signaling in mouse hepatocytes, and 
additionally allowed for the use of STRING to test for interactions between individual upstream 
regulators. As shown in Figure B.12, three upstream regulators in total did not have any 
predicted connections between themselves and other upstream regulators. Following further 
research, we discovered that there was very little in the primary literature that related mTORC1 
signaling to these three genes, indicating a likely novel relationship and an unexplored area of 
mTORC1 signaling in the liver 
    A literature search for Sirt2, a protein from the family of NAD-dependent deacetylases, 
revealed heterogeneous activity in the liver. Sirt2 has been discovered to facilitate liver glucose 
uptake, and its overexpression enabled metabolically obese mice to overcome their glucose 
intolerance via increased glucose uptake. A knockdown in non-diabetic mice induced glucose 
intolerance and decreased hepatic glucose uptake (88). Our results indicated inhibition of Sirt2 in 
an mTORC1 KO genotype, indicating a potential of hepatic glucose intolerance in patients 
treated with rapamycin or rapalogs due to their suppression of mTORC1 activity. However, Sirt2 
overexpression was found to be a predictor of poor survival and increased metastatic events in 
patients with HCC (89), as well as a promoter of increased hepatic fibrosis (90), indicating that 
while mTORC1 suppression may lead to specific off target effects, some of these effects may not 
be clinically detrimental.  
     Kdm5b, a type of lysine-specific demethylase, also lacked any known connection to 
mTORC1, with its most notable association being a prognostic factor for hepatocellular 
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carcinoma, in which increased Kdm5b expression was found to promote tumor cell progression 
and was associated with a poor prognosis in clinical samples (91). Our results indicated that 
mTORC1 knockout inhibited Kdm5b, indicating a possibility for the use of mTORC1 inhibitors 
in Kdm5b-driven HCC.  
     Hoxa10, part of a family of homeobox transcription factors, was another potential clinical 
target, with a recent study pointing to its knockdown as suppressive in an in vitro and an in vivo 
model of HCC (92). As was the case for Kdm5b, we noted an inhibition of Hoxa10 in mTORC1 
KO IPA results, indicating that Hoxa10, along with Kdm5b, could be a possible clinical target 
for HCC treatment.  
     While any translational relevance from the above results is clearly preliminary, a noted 
discovery is the association of mTORC1 with these three proteins, all of which play a role in 
significant human morbidity and mortality. Further research should be aimed at elucidating the 
mechanisms by which mTORC1 signaling mediates changes in the expression of these three 
genes. Additional attention should also focus on the effects of mTORC1 inhibition in treatment 
of advanced HCC driven by these genes, from which significant clinical benefit may result.  
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4.5.2 mTORC2 Results 
     IPA results of upstream regulator analysis for mTORC2 KO RNA-seq shortlist data yielded 
five total genes that did not have any known association with the other upstream regulators 
identified, with results shown from STRING analysis in Figure B.13. A literature review yielded 
potential translational implications for mTORC2 inhibition in the context of these five genes, all 
of which were predicted to be inhibited in an mTORC2 KO genotype.  
     With respect to liver lipid balance, two of the five genes noted in IPA results have a defined 
role in liver lipid homeostasis. The zinc finger protein Zbtb20 is known to promote de-novo 
hepatic lipid synthesis (93), and its absence is defined by hypolipidemia and impaired lipid 
synthesis in mouse hepatocytes. The retinoic acid receptor-related orphan receptor ROR𝛼 also 
controls liver lipid homeostasis through its interactions with PPAR𝛾, with mice lacking ROR𝛼 
developing steatohepatitis, obesity, and diabetes (94). Interestingly, Zbtb20 downregulation as 
predicted by our IPA results would lead to hypolipidemia, the opposite of which would likely 
occur in ROR𝛼 downregulation. While the clinical significance of these two divergent effects 
following mTORC2 KO requires significant further study, our results give evidence that a novel 
relationship exists between mTORC2 signaling and these two proteins, thus adding to the 
understanding of the mechanisms relating liver lipid balance and mTOR signaling.  
     MLX was a unique finding in our IPA analysis, as it functions as a transcription factor only 
after heterodimerizing with ChREBP. Together, MLX-ChREBP act as a response element to 
glucose, with a key function of this heterodimer being the upregulation of fatty acid synthase 
transcription following increased glucose levels in the liver (95). Mice with a disruption in 
ChREBP or a dominant negative form of MLX do not have induction of liver lipogenesis 
following carbohydrate stimulation (95). Our results indicate that MLX is inhibited in an 
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mTORC2 KO genotype, pointing to both a novel mTORC2-mediated regulation of lipogenesis 
control in the liver, as well as a potential mechanism by which excessive lipogenesis may be 
targeted.   
     Etv5 was the least studied of all genes that we discovered during our analysis, with no 
research found in PubMed relating its activity to the liver, mTORC2, or mTOR signaling in 
general. However, our results indicate that there is a relationship between mTORC2 knockout 
and Etv5 inhibition, and that this does not appear to proceed through any of the other upstream 
regulators found during IPA. Therefore, further research should be completed, perhaps by the 
generation of liver-specific knockouts of Etv5 in order to determine its role, if any, in liver 
function.  
     PPAR𝛿 is additionally under researched both in respect to its function in the liver as well as 
its association with mTOR signaling. As was noted for Etv5, more mechanistic research is 
needed in order to elucidate the specific role that this gene plays in the liver, especially given that 
our current results point to a relationship between mTORC2 inhibition and PPAR𝛿 inhibition.  
4.6 IPA allows for a complete picture of mTOR signaling in both wild-type and knockout 
genotypes 
     Next-generation analysis using IPA allows for the construction of signaling pathways in ways 
that were not previously possible. In conjunction with upstream analysis, we generated a 
signaling pathway with either mTORC1 or mTORC2 in the center, as visualized in Figures B.14 
and B.15, respectively. As our results from upstream analysis showed the predicted activation 
states in the case of an mTORC1 or mTORC2 knockout phenotype, we wanted to determine 
what a wild-type signaling pathway would conceivably look like in hepatocytes.  
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     Our results indicate that mTORC1 and mTORC2 signaling initiates with some similarities, as 
both mTORC1 and mTORC2 signaling initiates through SREBF1. However, similarity ends at 
that point, with mTORC1 signaling additionally activating SREBF2 and deactivating CREB, 
leading to a unique mTORC1-specific downstream signaling response, visualized in Figure 
B.14. mTORC2 (Figure B.15), on the other hand, brings about downstream signaling via 
activation of entirely different transcription factors, and notably differs from mTORC1 signaling 
in that all downstream effectors are activated.  
     In combination with our discovery that there are multiple unique transcription factors 
functioning in hepatic mTORC1 and mTORC2 signaling, we have uncovered significant 
evidence that hepatic mTORC1 and mTORC2 signaling is divergent, and has multiple currently 
uncharacterized downstream proteins associated with its signaling. This is important both in 
understanding the basic mechanisms of hepatic mTOR signaling as well as in elucidating why 
responses to rapamycin and its associated rapalogs may be incomplete or ineffective at treating 
certain hepatic malignancies. While our data does not directly implicate one of the many 
downstream effectors perturbed in hepatic mTORC1 and mTORC2 knockout animals in the 
progression of HCC, it suggests that there are multiple possible targets that require further study. 
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CHAPTER 5 
CONCLUSION 
     mTORC1 and mTORC2 signaling in hepatocytes has been an area of recent interest, 
culminating with significant works by Lamming et.al and Boylan et.al that profiled the activity 
of mTOR signaling in mouse as well as Sprague-Dawley rat hepatocytes. However, the models 
used were not directly comparable to one another due to the differing ways that mTORC1 and 
mTORC2 were inhibited, and microarray analysis did not achieve whole genome analysis of 
mTORC1 and mTORC2 perturbations.  
   In our approach, we used a liver-specific knockout of mTORC1 or mTORC2, and performed 
RNA-seq and subsequent analysis using Metascape, GSEA, IPA, and STRING in order to 
thoroughly characterize the activity of mTORC1 and mTORC2 in the mouse hepatocyte. Our 
results have shown that there are specific genes that are perturbed following either mTORC1 or 
mTORC2 knockout, and that the enriched genes have a role in HCC, NAFLD, or a related 
human morbidity. Subsequently, we found common positive enrichments for ribosomal 
biogenesis, DNA repair, and certain immune functions, allowing for us to conclude a common 
role of both signaling complexes in these critical cell functions. Further analysis revealed that 
these enriched categories were composed almost entirely of ribosomal genes, indicating that 
while both complexes likely regulate these genes, there must be alternative pathways in the 
hepatocyte that are activated following mTOR perturbation. Results of IPA and STRING 
revealed multiple downstream targets of mTORC1 and mTORC2 in the mouse hepatocyte that 
have not been described in the literature, thus adding to basic understanding of mTOR signaling 
in the liver. These novel downstream targets were also closely associated with HCC and lipid 
homeostasis in the liver, indicating that altered mTOR signaling may be responsible for 
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pathological changes in hepatocytes. While these results do not yet elucidate a single target for 
HCC or liver lipid homeostasis in relation to mTOR signaling, the relatively low number of 
novel downstream effectors identified yields a narrow list of potential clinical targets. Our 
findings also allow for the generation of liver specific mTOR signaling pathways, which include 
the aforementioned novel downstream targets, thus adding to basic mechanistic knowledge of 
mTOR signaling in the liver.  
     In conclusion, we have made significant progress in elucidating the details of mTOR 
signaling in mouse hepatocytes. Our models have allowed for clean comparisons between 
mTORC1 and mTORC2 knockout hepatocytes, and have given detailed information of possible 
clinical targets for the treatment of HCC or lipid homeostatic disruption. More research is needed 
in order to fully elucidate the role of novel downstream targets of mTOR signaling in the liver, 
and our data yields a starting point for these future pursuits.  
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APPENDIX A  
TABLES 
 
 
 
A.1 List of genes differentially expressed in both mTORC1 and mTORC2 knockout groups 
 
A list of the 21 genes having translational relevance that were found to be differentially expressed in both mTORC1 
and mTORC2 knockout animals. Categories are listed for hepatocellular carcinoma, non-alcoholic fatty liver 
disease, and other human morbidities, and each gene is linked to articles that describe its role in one or more of the 
categories. 
Gene ID Known Function 
Via NCBI 
Hepatocellular 
Carcinoma 
Non-Alcoholic Fatty 
Liver Disease 
Other Human 
Morbidities 
Rgs16 (Regulator of 
g-protein signaling 
16) 
 
Inhibits signal transduction by increasing the GTPase 
activity of G protein alpha subunits 
----- 33 ----- 
Fasn (Fatty Acid 
Synthase) 
Multifunctional protein whose main function is to 
catalyze palmitate synthesis from acetyl CoA and 
malonyl CoA. This palmitate is then catalyzed into long-
chain fatty acids for storage  
20 ----- ----- 
Acot1 Acyl-CoA thioesterase 1 ----- 34 ----- 
Acot2 Acyl-CoA thioesterase 2 ----- 35 ----- 
Serpina12 Known as Vaspin in literature ----- 36 ----- 
Myc (proto-
oncogene myc) 
Encodes a nuclear phosphoprotein that plays a role in 
cell cycle progression and in apoptosis as well as cell 
cycle progression 
21 ----- ----- 
Adgrf1 Adhesion G-protein coupled receptor F1 ----- ----- 39 
Gna14 G protein subunit alpha 14 
Guanine-nucleotide binding protein that may play a role 
in pertussis-toxin resistant activation of phospholipase 
C-beta and its related downstream effectors 
22 ----- ----- 
Cyp26a1 Cytochrome p450 family 26 subfamily A member 1 
Endoplasmic reticulum protein that acts on retinoids, 
including all-trans-retinoic acid, and regulates the levels 
of retinoic acids in the cell 
23 ----- ----- 
Lepr Leptin receptor, involved in the regulation of fat 
metabolism as well as in a novel hematopoietic pathway 
that is necessary for normal lymphopoiesis  
32 ----- ----- 
Extl1 Exostosin-like glycosyltransferase  
Functions in the chain polymerization of heparan sulfate 
and heparin  
24 ----- ----- 
Cd36 Liver lipid transport gene expressed in the liver that 
functions to transport lipids from the blood into liver fat 
stores 
25 37 ----- 
Saa2 Serum amyloid A2 coding gene in humans and mus. 
Musculus  
Biased expression in liver, fat, and in lesser amounts in 
appendix 
26-28 ----- ----- 
Dpy19l3 Dpy-19 like c-mannosyltransferase 3  ----- ----- 41, 42 
Mid1ip1  MID1 interacting protein 1 ----- 38 ----- 
Agpat9 Lysophosphatidylcholine acetyltransferase 1, also known 
as Agpat9 
Plays a role in lipid metabolism, specifically in the 
conversion of lysophosphatidylcholine to 
phosphatidylcholine in the presence of Acetyl-CoA 
----- ----- 44, 45 
Chpf2 Chondroitin polymerizing factor 2 ----- ----- 40 
Mir671 microRNA 671 29 ----- ----- 
Gpc1 Glypican 1 
Cell surface heparan sulfate proteoglycan, may play a 
role in control of cell division and growth regulation  
----- ----- 43 
Mt1 Metallothionein 1 in mouse, human ortholog 
metallothionein 1 binds divalent heavy metals, alters the 
intracellular concentration of heavy metals in the cell 
30, 31 ----- ----- 
Srebf1 Transcription factor, responsible for regulating lipid 
balance in liver 
----- 97 ----- 
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A.2 mTORC1 KO Hallmark gene set enrichments  
 
A.3 mTORC1 KO Kegg and Reactome gene set enrichments  
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A.4 mTORC1 KO Gene Ontology gene set enrichments  
 
Shown above are GSEA enrichments for mTORC1 knockout RNA-seq shortlist data. An FDR q 
value of 0.1 or less and a normalized enrichment score (NES) ≤ −1.70 for negative enrichment 
and ≥ 1.70 for positive enrichment were used as selection criteria. All sets that met the cutoff are 
included here, and redundant gene sets were purged prior to assembly of final tables.  
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A.5 mTORC2 KO Reactome gene set enrichments  
 
A.6 mTORC2 Gene Ontology gene set enrichments  
 
Shown above are GSEA enrichments for mTORC2 knockout RNA-seq shortlist data. An FDR q 
value of 0.1 or less and a normalized enrichment score (NES) ≤ −1.70 for negative enrichment 
and ≥ 1.70 for positive enrichment were used as selection criteria. All sets that met the cutoff are 
included here, and redundant gene sets were purged prior to assembly of final tables.  
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A.7 List of common GSEA enrichments for mTORC1 and mTORC2 KO group  
 
 
 
Shown above is a list of enriched categories that were found in both mTORC1 and mTORC2 
knockout GSEA results. Identical selection criteria were used, and redundant results were purged 
prior to creation of the final table. 
 
 
 
  
	
Enrichment	ID	 mTORC1	 mTORC2	
NES	 FDR	q	
Value	
NES	 FDR	q	
Value	
Kegg_ Ribosome 
	
2.47	 0	 2.77	 0	
Reactome_ nonsense_ mediated_ decay_ 
NMD_independent_ of _the_ exon junction complex _EJC 
	
2.43	 0	 2.60	 0.003	
Reactome _eukaryotic_ translation _initiation 
	
2.36 
	
0 
	
2.53	
	
0.009	
	
Reactome_ SRP _dependent_ cotranslational protein 
targeting_ to _membrane 
	
2.33 
	
0	 2.5	
	
0.011	
Reactome_Nonsense_Mediated_Decay_NMD	
	
2.27	 0	 2.47	 0.012	
Reactome_ rRNA _processing _in_ the nucleus_ and 
_cytosol 
	
2.15	 0.003	 2.48	 0.012	
Reactome_ rRNA _processing 
	
2.11	 0.007	 2.49	
	
0.011	
Reactome_Influenza_Infection	
	
2.13	 0.005	 2.42	 0.027	
Reactome_Selenoamino_Acid_Metabolism	
	
2.09 
	
0.008	 2.5	 0.011	
GO_cytosolic_ribosome	
	
2.4 
	
0 
	
2.58	
	
0.001	
GO_cytosolic_large_ribosomal_subunit	
	
2.3	
	
0.0009
3	
2.51	
	
0.023	
GO_Cotranslational_Protein_Targeting_To_Membrane	
	
2.4	
	
0	 2.47	
	
0.034	
	
GO_Cytosolic_Small_Ribosomal_Subunit	
	
2.01	
	
0.08	 2.46	
	
0.028	
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APPENDIX B 
 FIGURES 
B.1 Metascape enrichments of mTORC1 KO shortlist data  
 
 B.2 Metascape enrichments of mTORC2 KO shortlist data  
 
B.3 Metascape enrichments of 23 common genes  
  
B.4 Venn diagram of mTORC1 and mTORC2 KO differentially expressed genes  
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B.5 RNA-seq analysis of Raptor and Rictor expression, and western immunoblot analysis of mTORC1 and 
mTORC2 experimental groups  
 
  
 
Metascape enrichments are shown above for mTORC1 in Figure B.1, and for mTORC2 in Figure 
B.2. Red indicates a unique enrichment, blue a common enrichment, and yellow an enrichment 
that is novel in its relationship to either mTORC1 or mTORC2. Metascape enrichments for the 
23 genes differentially expressed in both mTORC1 and mTORC2 KO datasets are shown in 
Figure B.3. Figure B.4 provides a Venn diagram overview of the overlap between mTORC1 and 
mTORC2 knockout datasets, as well as the total number of genes differentially expressed in both 
complex’s data sets. Immunoblots for mTORC1 and mTORC2 experimental groups are shown in 
Figure 1.e, with 𝛽-Actin loading controls used for both experimental groups. Loading of gels 
was completed in duplicate for WT and KO groups for both experiments. A complementary 
addition of Raptor and Rictor KO RNA-seq expression data is included as supplement.  
 Gene 
 
log2(Ratio) 
 
q Value 
 
mTORC1 
KO 
Rptor 
 
-1.69 True 
 
mTORC2 
KO 
Rictor 
 
-0.31 
 
False 
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 B.6 IPA canonical pathway enrichments for mTORC1 KO  
 
 
 B.7 IPA disease enrichments for mTORC1 KO  
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 B.8 IPA canonical pathway enrichments for mTORC2 KO  
IPA readouts for enriched biological pathways and disease 
pathways for mTORC1 are shown in Figures B.6 and B.7, 
respectively. The top 15 enriched categories were used for 
both figures. IPA readouts for mTORC2 biological 
pathways and disease pathways are shown in Figures B.8 
and B.9, respectively. Enrichment z scores are shown in 
orange for positive, blue for negative, white for zero, and 
grey if no activity relationship was calculated in IPA.  
 
 B.9 IPA disease enrichments for mTORC2 KO  
 
  
53 
B.10 IPA upstream regulator analysis for mTORC1 KO  
 
 
B.11 IPA upstream regulator analysis for mTORC2 KO  
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B.12 STRING analysis of IPA upstream regulators for mTORC1 KO  
 
       
Upstream regulator analysis results are shown for  
mTORC1 KO shortlist data in Figure B.10, and for mTORC2 shortlist data in Figure B.11. 
Upstream regulators are defined as those predicted by IPA to be upstream of the RNA-seq 
shortlist genes, and downstream of mTORC1 or mTORC2, respectively. Activation z-scores and 
p-values of overlap are listed for each upstream regulator, with orange indicating predicted 
activation and blue indicating predicted inactivation. STRING protein interaction networks are 
shown for mTORC1 upstream regulator analysis in Figure B.12, and for mTORC2 upstream 
regulator analysis in Figure B.13. Proteins with no calculated interaction or association 
relationship are shown as separate circles for mTORC1 in Figure B.12 and mTORC2 in Figure 
B.13.  
 
 
  
 
 
 
 
 
 
 
B.13 STRING analysis of IPA upstream regulators for mTORC2 KO 
        
 regulators for mTORC2 KO 
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B.14 mTORC1 downstream signaling pathway based on IPA results  
 
Figure B.15 mTORC2 downstream signaling pathway based on IPA results  
 
 
The predicted signaling downstream of mTORC1 and mTORC2 is shown above in Figures B.14 
and B.15, respectively. Green indicates activation, and red indicates inactivation, with white 
indicating an indirect relationship. These figures display active mTOR signaling through the 
upstream regulators described in Figure B.10 and B.11. The activation status of upstream 
regulators in inactive mTOR signaling is the exact opposite of what is found in active signaling, 
with green indicating inactivation and red indicating activation in that scenario. 
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APPENDIX C 
 
SUPPLEMENTAL ANNOTATION OF GENES 
 
Genes Involved in Hepatocellular Carcinoma/Liver Cancer: 
     Fatty acid synthase (Fasn) was found to be critical in the abrogation of HCC progression in 
mice that had Akt dependent HCC, as evidenced by HCC progression in mice with KO Fasn 
(20).  
     For Myc, a recent study noted that in hepatocellular carcinoma, p53 mutant cancers that are 
addicted to Myc stabilization and driven by KRas are treatable by inhibition of Myc stabilization 
by AURKA (21).  
     Gna14 was found to be a hub gene for HCC, and may also play a role as a tumor marker for 
diagnosis, staging, and treatment of HCC (22). 
      Cyp26a1, one of the many cytochrome genes, was downregulated in expression in an HCC 
cell line treated with non-toxic levels of a soybean flavone for 12 hours (23).  
     Extl1 was found to be upregulated and differentially methylated in C3H mice, serving as a 
model for HCC progression (24). 
      Research on the physiological role of CD36 has implicated it in the development of HCC, 
with the proposed mechanism being increased transport of free fatty acids into the liver leading 
to an epithelial-mesenchymal transition, thereby promoting HCC metastasis (25). 
      Saa2 was found in the blood sera of a sample of 31 patients with HCC, indicating that it 
could serve as a biomarker for the condition (26). Additionally, it was found to be decreased 
upon insulin treatment of hepatoma cell line, assumed to be an inflammatory response gene due 
to its association with IL-6 signaling (27). The same research group that proposed Saa2 as an 
inflammatory response gene also found that small molecule activation of AMP-activated protein 
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kinase (AMPK) repressed IL-6 signaling and the pro-inflammatory molecule Saa2, indicating 
that AMPK is a master regulator of inflammatory and metabolic pathways in hepatocytes, among 
them Saa2 (28).  
      Mir671, a microRNA, was found to be upregulated in samples of microvesicles, a type of 
extracellular vesicle released from the cell membrane, from patients with HCC (29).  
     Mt1, a metallothionein, was found to be downregulated in in human HCC samples, opening 
for the possibility of its use as a biomarker (30). It was also found that loss of nuclear expression 
of Mt1 was associated with a poor prognosis for HCC in a sample of 370 patients with the 
disease (31).  
     Research on cirrhotic liver samples that were also infected with hepatitis C showed that the 
most common mutation was in the leptin receptor gene. This held true for both tumor and non-
tumor cirrhotic liver samples, indicating that accumulation of mutations in the LEPR gene and 
may lead to hepatocellular carcinoma characterized by altered LEPR signaling (32). 
Genes Involved in NAFLD/Fatty Liver: 
      Rgs16, known as the Regulator of G-protein signaling 16, was found in a recent study to be 
responsible for development of fatty liver in mice that had transgenic Rgs16 introduced into their 
hepatocytes, which was connected to a tetracycline-sensitive promoter. Mice that were fed with 
doxycycline, a type of tetracycline antibiotic, in their water subsequently developed fatty liver 
deposits (33). 
     For the two Acot (Acyl-CoA thioesterase) genes, a knockdown of Acot1 in mouse 
hepatocytes resulted in increased hepatic oxidative stress and inflammation, both a hallmark of 
NAFLD (34). Interestingly, a knockdown of the same gene in mice with diet-induced hepatic 
steatosis resulted in a liver lipid content similar to controls, showing that while knockdown alone 
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could result in oxidative stress and inflammation, knockdown may also play a protective role 
against diet-inducted hepatic steatosis (34). The role of Acot2 was significantly less researched, 
however, a recent report in the literature noted that its likely role was functioning as an enhancer 
of fatty acid oxidation in the mitochondria, the likely mechanism being prevention of chemical 
intermediate accumulation in the mitochondrial matrix (35) 
     Serpina12, known commonly as Vaspin, was found to be positively associated with 
inflammation, serum glucose levels, and insulin resistance in a pool of patients with NAFLD 
(36).  
     CD36, the only gene found with research suggesting its role in both HCC and NAFLD, with 
previous research in our lab suggesting a reprogramming of liver lipid metabolism in offspring 
upon treatment of mice with the flame retardant PBDE-47 during gestation. This relationship 
was noted to be multidirectional- in low doses of PBDE-47, CD-36 expression decreased, and 
subsequently blood lipid levels increase, while moderate doses lead to increased CD36 
expression and histological liver changes consistent with NAFLD (37). 
     In the B cells of the Pancreas, ChREBP regulates the expression of multiple lipogenic genes, 
among them Mid1ip1. It was found to be both necessary and sufficient to induce the expression 
of 15 lipogenic genes, and the function of Mid1ip1 appears to be upregulation of Acaca, an 
enzyme that catalyzes the carboxylation of acetyl-CoA to Malonyl-CoA (38).  
     Finally, Srebp1-c, the protein product of the Srebf1 gene, was found to induce fatty liver 
development in mice with a albumin promoter controlled overexpression of Srebf1, indicating 
that NAFLD may be mediated by increased Srebf1 signaling. 
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Genes Functioning in other Human Diseases: 
      A genome-wide analysis of mice that had significant atherosclerotic lesion formation found 
that the H2 major histocompatibility locus contained 12 candidate genes, among them Adgrf1, 
that were significantly associated with coronary heart disease. This indicates that Adgrf1 may 
mediate the inflammation that promotes atherosclerosis (39).  
     Chpf2 was found to be one of the several chondroitin sulfate-linked genes that were found to 
be mutated in 1/3 of a sample of 26 patients who had experienced a thrombotic storm, a rare type 
of clotting event that is characterized by severe, acute multiple clotting events often affecting 
young adults (40).  
    Dpy19l3 was recently discovered to function in c-mannosylation, a rare type of protein 
glycosylation (41). Its target protein, RPE-spondin, was found to be expressed at high levels in 
certain colon cancer cell lines, implicating RPE-spondin, and its putative regulator, Dpy19l3 
(42). 
     In other works, Gpc1 was recently found to be associated with susceptibility to biliary atresia, 
a rare childhood disorder of the biliary tree that results in end stage hepatic disease (43).  
     Agpat9, part of a group of related proteins that acylate lysophosphatidic acid at an Sn2 
position to produce phosphatidic acid, was initially discovered and found to be expressed in lung 
and spleen tissue, with its hypothesized role being synthesis of triglycerides and phospholipids in 
these tissues (44). Interestingly, recent research on the antimetabolite antineoplastic agent 5-
azacytidine, used to prolong life in patients with acute myeloid leukemia, noted that significant 
upregulation in Agpat9 expression, mediated by the inhibitory effect 5-azacytidine displays on 
UMP (45). Together, these observations led to a conclusion that 5-azacytidine reprograms lipid 
metabolism in an epigenetic manner via hypomethylation of DNA, and that Agpat9 disruption, 
60 
along with UMP inhibition, is a possible mechanism of increased lipogenesis observed in the 
patient cohort (44,45). 
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